Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,469 across all filing types
Latest filing 2025-12-16 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of shares by the issuer (Ascletis Pharma Inc.) on the exchange, providing specific dates, quantities, and prices. This falls under the category of a company reporting its own share buyback activity, which is classified as 'Transaction in Own Shares'.
2025-12-16 English
VOLUNTARY ANNOUNCEMENT - UPSIZING OF PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE
Transaction in Own Shares Classification · 1% confidence The document is a voluntary announcement from Ascletis Pharma Inc. regarding the 'Upsizing of Proposed Share Repurchase'. It details the board's decision to increase the share repurchase fund from HK$300 million to HK$500 million, explains the rationale (undervalued stock, business milestones), and confirms compliance with the Repurchase Mandate. While it mentions share repurchases, it is an announcement of a change in the repurchase plan rather than a report of specific transactions in own shares (which would be a POS filing). Given the nature of the announcement regarding capital allocation and share repurchase strategy, it fits best under 'Capital/Financing Update'.
2025-12-16 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE I STUDY OF ASC50, A POTENTIAL BEST-IN-CLASS ORAL SMALL MOLECULE IL-17 INHIBITOR
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the positive topline results of a Phase I clinical trial for their drug candidate ASC50. It details the clinical findings, safety profile, and future development plans, and includes a notice for an upcoming conference call. Since it is a general corporate announcement regarding business/clinical development that does not fit into specific categories like financial reports, M&A, or director dealings, it is classified as a Regulatory Filing (RNS).
2025-12-15 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details specific transactions involving the repurchase of shares by the issuer (Ascletis Pharma Inc.) on a specific date (12 December 2025). According to the filing definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2025-12-12 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT (ASC40), A FIRST-IN-CLASS FASN INHIBITOR FOR ACNE TREATMEN
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Ascletis Pharma Inc. regarding the acceptance of a New Drug Application (NDA) by the China National Medical Products Administration (NMPA) for a specific drug (denifanstat). It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general regulatory announcement regarding business development and clinical trial progress that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2025-12-10 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS' ORAL SMALL MOLECULE GLP-1, ASC30, DEMONSTRATED PLACEBO-ADJUSTED WEIGHT LOSS OF 7.7% WITH BETTER GASTROINTESTINAL TOLERABILITY IN ITS 13-WEEK U.S. PHASE II STUDY
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Ascletis Pharma Inc. regarding the positive topline results of a Phase II clinical trial for their drug candidate ASC30. It details clinical trial data, efficacy, safety profiles, and mentions upcoming conference calls to discuss these results. This fits the definition of a regulatory announcement regarding business and clinical development, which is best classified as a Regulatory Filing (RNS) as it does not constitute a full financial report, a transcript, or a specific investor presentation deck.
2025-12-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.